Kenning
Not started
Quick win kit · 7 days · yours forever

You know the number.
Getting there is the problem.

Every calculator on the internet will tell you how much protein you need. None of them help when you are full after four bites and the thought of chicken makes you turn away. There are several different reasons women miss protein on these medications and they need completely different fixes. This kit works out which one is yours, gives you five days aimed at that, and measures whether it moved.

Eight question read Five days, measured in grams Checks that this stays healthy A page for your prescriber Reusable at every dose increase
ONE

First, what is actually stopping you?

Six women, six completely different problems. Only one of them is yours.

Generic advice speaks to none of them. Eight questions, about two minutes, and you will know which is yours.

FOUR

When eating less stops being the medication working

Less appetite is the point. Less nourishment is not.

There is a line between the two, and nobody tells you where it is. Here it is.

Read this once now, while you are fine. Neither list below is a failure of willpower, and both are far more common than anyone says out loud.

Talk to your prescriber this week if

  • You are managing less than the equivalent of one small meal on most days
  • You are losing weight noticeably faster than your prescriber expected
  • You are cold all the time, exhausted, and your hair has started shedding
  • You feel dizzy or lightheaded when you stand up

Ask for help sooner if

  • You are making yourself sick, or using the medication to eat as little as possible
  • You feel out of control around food, or frightened of eating
  • You have not been able to keep fluids down for a full day
That second list is not a judgement, and it is not rare.
Nearly a third of people with an eating disorder report having used one of these medications. Decades of being told to eat less, and then a drug that removes hunger altogether, is a hard combination to notice from the inside. If any of it is familiar, this kit will stop giving you targets and point you somewhere more useful instead.
Developed by Kenning’s clinical and outcomes research team. Educational only and not medical advice.

If this happens again

You will not be starting over. When it comes back, most often at your next dose increase:

  1. Reopen this kit.
  2. Your previous plan is already saved.
  3. Compare what you are managing now against your last round.
  4. Change one thing at a time, so you learn something.
References
  1. Lean mass during weight loss. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(suppl 4):16-27. doi:10.1111/dom.15728. Reports genuine heterogeneity rather than a single figure: lean mass was 45.2 percent of weight lost in STEP-1 and 25.7 percent in SURMOUNT-1, with some studies at 15 percent or less.
  2. Tinsley GM, Heymsfield SB. Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. J Endocr Soc. 2024;8(11):bvae164. doi:10.1210/jendso/bvae164. Establishes that fat free mass is not synonymous with skeletal muscle, and discusses resistance training and protein as countermeasures.
  3. Protein during weight loss in older adults. Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542-559. doi:10.1016/j.jamda.2013.05.021. At least 1.0 to 1.2 g/kg/day for people over 65, more with illness or exercise.
  4. Volkert D, Beck AM, Cederholm T, et al. ESPEN practical guideline: clinical nutrition and hydration in geriatrics. Clin Nutr. 2022;41(4):958-989. doi:10.1016/j.clnu.2022.01.024. At least 1 g/kg/day, individually adjusted for nutritional status, activity, disease and tolerance. Grade B, strong consensus. Neither of these is specific to GLP-1 therapy, and neither is a prescription for an individual.
  5. Nutrition guidance during GLP-1 therapy. Spreckley M, Ruggiero CF, Brown A. Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery. Int J Obes. 2025. doi:10.1038/s41366-025-01952-w.
  6. Reduced intake is the mechanism. World Health Organization. WHO guideline on the use of GLP-1 therapies for the treatment of obesity in adults. Geneva: WHO; December 2025. Positions these therapies within comprehensive care including diet, activity and professional support.
  7. Nausea, dose dependence and escalation. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551. Nausea affected 43.9 percent on semaglutide 2.4 mg against 16.1 percent on placebo, reported more frequently during dose escalation, with cumulative incidence plateauing after week 20.
  8. Misreporting of intake. National Cancer Institute, Division of Cancer Control and Population Sciences. Dietary Assessment Primer: measurement error. Against recovery biomarkers, energy is seriously misreported, by 6 to 26 percent on 24 hour recalls. Protein is far better estimated, ranging from 13 percent under to 19 percent over on recalls, and about 4 percent on food records. This kit therefore claims only that a written record beats memory, not that women systematically underestimate protein.
  9. Freedman LS, Commins JM, Moler JE, et al. Pooled results from 5 validation studies of dietary self-report instruments using recovery biomarkers for energy and protein intake. Am J Epidemiol. 2014;180(2):172-188. doi:10.1093/aje/kwu116.
  10. Disordered eating and medication misuse. Jebeile H, Baur LA, Kwok C, et al. GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: a rapid review of changes in eating behaviors and eating disorder risk. Obes Rev. 2025;26(12):e70049. doi:10.1111/obr.70049. Twenty five studies, 8,997 participants. Concludes the evidence base is still limited and that monitoring is appropriate.
  11. Peiper NC, et al. Use and misuse of GLP-1 receptor agonists among individuals with eating disorders. Interim cross sectional analysis, 2026. Nearly one third of respondents with an eating disorder reported lifetime use of a GLP-1 receptor agonist, with misuse more frequent than in the general population. Cited as the basis for screening, not as a prevalence estimate for the general population.
  12. National Association of Anorexia Nervosa and Associated Disorders. GLP-1 medications and eating disorders. 2026. Grey literature. Cited for the position that screening before and monitoring during treatment is appropriate.

Two things these sources changed in this kit. The widely repeated figure that around 40 percent of weight lost on these medications is muscle is not supported as a general claim: the range across trials runs from about 15 to 60 percent, it differs by drug, and lean mass on a scan is not the same thing as skeletal muscle. And while energy intake is badly misreported from memory, protein specifically is estimated reasonably well, so this kit no longer suggests you are probably eating less protein than you think. It suggests only that writing it down beats remembering it.

Developed by Kenning’s clinical and outcomes research team. Educational only and not medical advice. Population specific thresholds pending clinical sign off.